Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...

Therapeutics announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lemaitre Vascular (LMAT – Research Report), ...

Native Instruments' NKS Hardware Partner Program launches today, bringing NKS compatibility to owners of a handful of its ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.

Nektar announces clinical trial agreement to evaluate rezpegaldesleukin in patients with new onset type 1 diabetes mellitus: San Francisco Tuesday, February 25, 2025, 18:00 Hrs [I ...

Nektar Therapeutics’s NKTR share price has surged by 22.00%, which has investors questioning if this is right time to sell.

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’t ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...